Founded in 2018, the corporate venture arm of a leading global Contract Research, Development and Manufacturing Organization is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The fund primarily seeks opportunities in the US, and is open to China and Europe as well. The fund does not lead rounds and prefers companies with a lead investor in place. Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The fund makes equity investments only and does not have an equity-for-service model.
Separately from the corporate venture arm, the parent corporation also runs a program which collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biotech assets development. Startups must be an active participant or referred by a Program Partner to be eligible.
The fund will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy.
The fund does not lead investments rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first-time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment